ClinicalTrials.gg
CompletedNCT00069095Updated Oct 6, 2016Results posted

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

A Phase 3 interventional study of Oxaliplatin 130 mg/m^2 and Capecitabine 1000 mg/m^2 in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 236 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,035
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
4th of 183
2,035 · median 50
Started
2003
with 12 others
Phase 3
36 of 206
4 open now
Registered
35th of 206
by date
Lead sponsor
11 of 206
Hoffmann-La Roche

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 4th largest by enrollment of the 183 interventional ones that give a count, is one of 13 that started in 2003, is one of 36 in phase 3, and was the 35th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 1) XELOX (Xeloda 1000 mg/m\^2 orally [po] twice a day [bid] on Days 1-15 + oxaliplatin in 3 week cycles), 2) FOLFOX-4 (oxaliplatin + leucovorin + fluorouracil [5-FU] in 2 week cycles), 3) XELOX + bevacizumab (7.5 mg iv on Day 1 in 3 week cycles), or 4) FOLFOX-4 + bevacizumab (5 mg iv on Day 1 in 2 week cycles).

Read the detailed description

This study was conducted in 2 parts: An initial 2-arm part in which patients were randomized to 1 of 2 different treatment groups (XELOX or FOLFOX-4), and a subsequent 2 x 2 factorial part, added to the study through a protocol amendment, in which additional patients were randomized into one of 4 different treatment groups (XELOX + placebo, FOLFOX-4 + placebo, XELOX + bevacizumab, or FOLFOX-4 + bevacizumab). Due to the comparison of the oral agent capecitabine with bolus and infused fluorouracil, the study was not blinded with respect to these 2 treatments. The study was double-blind with regard to the administration of bevacizumab, ie, there was a placebo control for bevacizumab in the second part of the study.

The study consisted of 3 phases, a Primary Study Treatment Phase, a Post-Study Treatment Phase, and a Follow-Up Phase.

Primary Study Treatment Phase

Patients were to receive up to 16 cycles (2-arm part of the study) or 24 cycles (4-arm part of the study) of treatment during the Primary Study Treatment Phase (48 weeks).

Post-Study Treatment Phase

Patients who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Patients who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the patient withdrew consent.

Follow-up Phase

Patients who terminated study treatment during the primary or post-study treatment phase were followed until disease progression or death.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥ 18 years of age.
  • colorectal cancer.
  • ≥ 1 target lesion.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with oxaliplatin or bevacizumab.
  • Previous systemic chemotherapy or immunotherapy for advanced or disease.
  • Progressive disease during or within 6 months of completion of previous therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
2,035 participants (actual)

Study arms

  • Experimental
    XELOX (oxaliplatin+capecitabine)

    Patients in the 2-arm part of the study received oxaliplatin 130 mg/m\^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m\^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.

    Drug: Oxaliplatin 130 mg/m^2 · Drug: Capecitabine 1000 mg/m^2 · Drug: Placebo for bevacizumab 7.5 mg/kg

  • Experimental
    XELOX (oxaliplatin+capecitabine) + bevacizumab

    Patients in the 4-arm part of the study received oxaliplatin 130 mg/m\^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m\^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.

    Drug: Oxaliplatin 130 mg/m^2 · Drug: Capecitabine 1000 mg/m^2 · Drug: Bevacizumab 7.5 mg/kg

  • Active comparator
    FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)

    Patients in the 2-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.

    Drug: Oxaliplatin 85 mg/m^2 · Drug: Leucovorin 200 mg/m^2 · Drug: Fluorouracil 400 mg/m^2 · Drug: Placebo for bevacizumab 5 mg/kg

  • Active comparator
    FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab

    Patients in the 4-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.

    Drug: Oxaliplatin 85 mg/m^2 · Drug: Leucovorin 200 mg/m^2 · Drug: Fluorouracil 400 mg/m^2 · Drug: Bevacizumab 5 mg/kg

Interventions

  • DrugOxaliplatin 130 mg/m^2

    Drug page: Oxaliplatin

    Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.

    Also known as: Eloxatin

  • DrugCapecitabine 1000 mg/m^2

    Drug page: Capecitabine

    Capecitabine was taken within 30 min after the end of breakfast and dinner.

    Also known as: Xeloda

  • DrugBevacizumab 7.5 mg/kg

    Drug page: Bevacizumab

    Bevacizumab was administered in a 30 to 90 min infusion.

    Also known as: Avastin

  • DrugPlacebo for bevacizumab 7.5 mg/kg

    Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.

  • DrugOxaliplatin 85 mg/m^2

    Drug page: Oxaliplatin

    Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.

    Also known as: Eloxatin

  • DrugLeucovorin 200 mg/m^2

    Drug page: Leucovorin

    Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.

  • DrugFluorouracil 400 mg/m^2

    Drug page: Fluorouracil

    Also known as: Efudex

  • DrugBevacizumab 5 mg/kg

    Drug page: Bevacizumab

    Bevacizumab was administered in a 30 to 90 min infusion.

    Also known as: Avastin

  • DrugPlacebo for bevacizumab 5 mg/kg

    Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4

    PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  2. PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

Secondary outcomes

  1. PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4

    PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  2. PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  3. PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4

    PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  4. PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  5. PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4

    PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  6. PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  7. Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4

    Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  8. Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

    Time frame: Baseline until disease progression or death, approximately 2 years 6 months

  9. Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4

    According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  10. Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  11. BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

    According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  12. BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  13. Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

    Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  14. Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  15. Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

    For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: Week 1 to Week 54

  16. Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

    Time frame: Week 1 to Week 54

  17. Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

    Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  18. Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone

    Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  19. Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

    For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

  20. Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

    For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

    Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months

07

Results

Posted Jan 22, 2016

Participant flow

This study was conducted in 32 countries - Australia, Austria, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Mexico, New Zealand, Norway, Panama, Portugal, Russia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey and USA.

Primary Treatment Phase
Participant flow — Primary Treatment Phase
MilestoneXeloxFolfox-4Xelox+PFolfox-4+PXelox+BVFolfox-4+BV
Started317317350351350349
Completed221536314848
Not completed295302314320302301
Withdrew: Ongoing005774
Withdrew: Admin/other293831454842
Withdrew: Adverse event99927172109101
Withdrew: Death1482588
Withdrew: Failure to return550002
Withdrew: Insufficient therapeutic response131127175154101102
Withdrew: Refused treatment152617312427
Withdrew: Withdrew238249
Withdrew: Other violation011101
Withdrew: Violation criteria024315
Post-study Treatment Phase
Participant flow — Post-study Treatment Phase
MilestoneXeloxFolfox-4Xelox+PFolfox-4+PXelox+BVFolfox-4+BV
Started81321173629
Completed000000
Not completed81321173629
Withdrew: Missing reason131281817
Withdrew: Adverse event231051
Withdrew: Eligible for surgery200000
Withdrew: Insufficient therapeutic response145679
Withdrew: Participant refusal/admin reasons100001
Withdrew: Participant had complete response110000
Withdrew: More than 21 days delay between cycles010000
Withdrew: Investigator decision (enough treatment)011010
Withdrew: Participant withdrew consent001000
Withdrew: Participant will start new treatment001000
Withdrew: Participant wanted break from treatment000100
Withdrew: Participant completed treatment000100
Withdrew: Surgery000110
Withdrew: Death000010
Withdrew: Participant had progressive disease000010
Withdrew: Participant/physician decision to stop000010
Withdrew: Preplanned 6 cycles after surgery000010
Withdrew: Investigator decision000001
Follow-up Phase
Participant flow — Follow-up Phase
MilestoneXeloxFolfox-4Xelox+PFolfox-4+PXelox+BVFolfox-4+BV
Started284299298299278272
Completed11093178187186171
Not completed17420612011292101
Withdrew: Death17420612011292101

Outcome measures

PrimaryProgression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4

PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4
daysFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4259 (245 to 268)241 (229 to 254)
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 1.05 · 97.5% CI 0.94 to 1.18
SecondaryPFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4
daysFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4304.0 (281 to 319)261.0 (246 to 276)
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 1.22 · 97.5% CI 1.05 to 1.42
SecondaryPFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
daysFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone259.0 (244 to 278)335.0 (310 to 363)
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.70 · 97.5% CI 0.58 to 0.83
SecondaryPFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4
daysFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4268.0 (252 to 290)234.0 (221 to 251)
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 1.24 · 97.5% CI 1.07 to 1.44
SecondaryPFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
daysFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone241.0 (227 to 254)316.0 (294 to 338)
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.63 · 97.5% CI 0.52 to 0.75
SecondaryPFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4
daysFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4260.0 (247 to 270)244.0 (230 to 255)
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 1.03 · 97.5% CI 0.92 to 1.15
SecondaryPFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
daysFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone245.0 (230 to 258)287.0 (276 to 300)
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = 0.0015 · Hazard ratio (hr): 0.83 · 97.5% CI 0.72 to 0.95
SecondaryOverall Survival: Non-inferiority of XELOX Versus FOLFOX-4

Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4
daysFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4549.0 (528 to 576)577.0 (535 to 615)
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 0.97 · 97.5% CI 0.84 to 1.14
SecondaryOverall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
daysFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone574.0 (537 to 592)551.0 (528 to 635)
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = 0.1921 · Hazard ratio (hr): 0.89 · 97.5% CI 0.72 to 1.09
PrimaryPFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

Time frame:
Baseline until disease progression or death, approximately 2 years 6 months
Reported as:
Median · days
PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
daysFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone244.0 (230 to 257)285.0 (271 to 297)
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = 0.0023 · Hazard ratio (hr): 0.83 · 97.5% CI 0.72 to 0.95
SecondaryBest Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4

According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Number · Percentage of responders
Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4
Percentage of respondersFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-449.446.4
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Odds ratio (or): 0.89 · 97.5% CI 0.72 to 1.09
SecondaryBest Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Number · Percentage of responders
Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Percentage of respondersFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone49.246.5
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Chi-squared · p = 0.3091 · Odds ratio (or): 0.90 · 97.5% CI 0.71 to 1.14
SecondaryBOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Number · Percentage of responders
BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
Percentage of respondersFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-438.637.1
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Odds ratio (or): 0.94 · 97.5% CI 0.76 to 1.16
SecondaryBOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Number · Percentage of responders
BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Percentage of respondersFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone37.537.5
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Chi-squared · p = 0.9887 · Odds ratio (or): 1.00 · 97.5% CI 0.78 to 1.28
SecondaryTime to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Median · days
Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
daysFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
General Approach191.0 (183 to 202)179.0 (171 to 187)
On-treatment Approach190.0 (182 to 200)176.0 (170 to 185)
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 1.08 · 97.5% CI 0.97 to 1.20
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 1.10 · 97.5% CI 0.98 to 1.23
SecondaryTime to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Median · days
Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
daysFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
General Approach183.0 (176 to 198)209.0 (199 to 220)
On-treatment Approach182.0 (175 to 196)208.0 (198 to 220)
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = 0.0030 · Hazard ratio (hr): 0.84 · 97.5% CI 0.74 to 0.96
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = 0.0004 · Hazard ratio (hr): 0.81 · 97.5% CI 0.70 to 0.92
SecondaryTime to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
Week 1 to Week 54
Reported as:
Number · Participants
Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
ParticipantsFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
Week 1-66793
Week 7-12190191
Week 13-18155110
Week 19-242538
Week 25-301413
Week 31-3673
Week 37-4231
Week 49-5420
SecondaryTime to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

Time frame:
Week 1 to Week 54
Reported as:
Number · Participants
Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
ParticipantsFOLFOX-4+P/XELOX+PXELOX/XELOX+P/XELOX+BV
Week 1-65848
Week 7-12146138
Week 13-1810587
Week 19-242629
Week 25-30712
Week 31-3628
Week 37-4212
Week 49-5401
SecondaryDuration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Median · days
Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
daysFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4239.0 (225 to 256)226.0 (211 to 246)
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 1.02 · 97.5% CI 0.86 to 1.22
SecondaryDuration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone

Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Median · days
Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone
daysFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone225.0 (217 to 240)257.0 (241 to 278)
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = 0.0307 · Hazard ratio (hr): 0.82 · 97.5% CI 0.66 to 1.01
SecondaryDuration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4

For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Median · days
Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
daysFOLFOX-4/FOLFOX-4+P/FOLFOX-4+BVXELOX/XELOX+P/XELOX+BV
Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4347.0 (196 to 403)589.0 (270 to NA)
Statistical analysis
  • FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV vs XELOX/XELOX+P/XELOX+BV · Hazard ratio (hr): 0.35 · 97.5% CI 0.09 to 1.39
SecondaryDuration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone

For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.

Time frame:
From baseline until disease progression/recurrence, approximately 2 years 6 months
Reported as:
Median · days
Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
daysFOLFOX-4+P/XELOX+PFOLFOX-4+BV/XELOX+BV
Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone403.0 (228 to NA)386.0 (133 to 386)
Statistical analysis
  • FOLFOX-4+P/XELOX+P vs FOLFOX-4+BV/XELOX+BV · Log Rank · p = 0.8207 · Hazard ratio (hr): 1.20 · 97.5% CI 0.20 to 7.05

Adverse events

Collected over Approximately 2 years 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Xelox—117/316 (37%)310/316 (98.1%)
Folfox-4—120/313 (38.3%)310/313 (99%)
Xelox+P—121/339 (35.7%)330/339 (97.3%)
Folfox-4+P—128/336 (38.1%)331/336 (98.5%)
Xelox+BV—131/353 (37.1%)348/353 (98.6%)
Folfox-4+BV—146/341 (42.8%)335/341 (98.2%)
Most frequent serious events
Showing 10 of 311
Most frequent serious events
EventXeloxFolfox-4Xelox+PFolfox-4+PXelox+BVFolfox-4+BV
DiarrhoeaGastrointestinal disorders27/31613/31325/3397/33626/3538/341
PyrexiaGeneral disorders16/31616/3136/33916/3367/35315/341
VomitingGastrointestinal disorders7/3167/31316/3392/33614/3537/341
Febrile neutropeniaBlood and lymphatic system disorders3/31614/3131/33915/3362/35314/341
DehydrationMetabolism and nutrition disorders4/3169/31310/3392/33610/3534/341
NeutropeniaBlood and lymphatic system disorders2/3169/3131/3396/3360/3535/341
Pulmonary embolismRespiratory, thoracic and mediastinal disorders9/3163/3133/3395/3369/3538/341
Intestinal obstructionGastrointestinal disorders4/3166/3136/3399/3364/3536/341
Central line infectionInfections and infestations1/3164/3131/3399/3360/3534/341
Abdominal painGastrointestinal disorders4/3167/3137/3396/3365/3537/341
Most frequent other events
Showing 10 of 69
Most frequent other events
EventXeloxFolfox-4Xelox+PFolfox-4+PXelox+BVFolfox-4+BV
NauseaGastrointestinal disorders194/316208/313209/339204/336230/353215/341
DiarrhoeaGastrointestinal disorders207/316186/313208/339197/336210/353218/341
NeutropeniaBlood and lymphatic system disorders88/316172/31390/339198/33670/353187/341
FatigueGeneral disorders132/316152/313118/339140/336133/353135/341
VomitingGastrointestinal disorders136/316123/313134/339127/336160/353127/341
Stomatitis AllGastrointestinal disorders63/316111/31376/339130/336101/353141/341
ParaesthesiaNervous system disorders116/316117/313126/339127/336133/353135/341
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders95/31630/313103/33936/336138/35346/341
EpistaxisRespiratory, thoracic and mediastinal disorders22/31641/31324/33962/33638/353107/341
AnorexiaMetabolism and nutrition disorders95/31693/31384/33986/336109/35396/341

Baseline characteristics

Baseline characteristics were described for the Intent-to-treat (ITT) population.This population included all randomized participants who provided written informed consent.

Age, Continuous
Age, Continuous(years)XeloxFolfox-4Xelox+PFolfox-4+PXelox+BVFolfox-4+BVTotal
Mean60.3 ± 10.7660.6 ± 10.9459.1 ± 12.1458.8 ± 10.8759.7 ± 11.2859.7 ± 10.7459.7 ± 11.14
Sex: Female, Male
Sex: Female, Male(Participants)XeloxFolfox-4Xelox+PFolfox-4+PXelox+BVFolfox-4+BVTotal
Female123113145165137144827
Male1942042051862132051207
08

Study locations

236 sites
  • Berkeley, California 94704, United States
  • Fountain Valley, California 92708, United States
  • Fullerton, California 92835, United States
  • Gilroy, California 95020, United States
  • Greenbrae, California 94904, United States
  • Los Angeles, California 90057, United States
  • Orange, California 92868, United States
  • Palo Alto, California 94304, United States
  • San Diego, California 92123, United States
  • Norwich, Connecticut 06360, United States
  • Waterbury, Connecticut 06708, United States
  • Boca Raton, Florida 33486, United States
  • Gainesville, Florida 33610-0277, United States
  • Jacksonville, Florida 32207, United States
  • New Port Richey, Florida 34652, United States
  • Tampa, Florida 33607, United States
  • Tampa, Florida 33647, United States
  • Atlanta, Georgia 30341, United States
  • Chicago, Illinois 60640, United States
  • Elk Grove Village, Illinois 60007, United States
  • Peoria, Illinois 61615-7828, United States
  • Lexington, Kentucky 40536-0098, United States
  • New Orleans, Louisiana 70121, United States
  • Scarborough, Maine 04074, United States
  • Boston, Massachusetts 02135, United States
  • Ann Arbor, Michigan 48106, United States
  • St Louis Park, Minnesota 55416, United States
  • Las Vegas, Nevada 89106, United States
  • East Orange, New Jersey 07019, United States
  • Hamilton, New Jersey 08690, United States
  • New Brunswick, New Jersey 08901, United States
  • Albuquerque, New Mexico 87131-0001, United States
  • Farmington, New Mexico 87401, United States
  • New York, New York 10065, United States
  • Rochester, New York 14623, United States
  • Syracuse, New York 13210, United States
  • Charlotte, North Carolina 28203, United States
  • Charlotte, North Carolina 28233-3549, United States
  • Bismarck, North Dakota 58501, United States
  • Fargo, North Dakota 58122, United States
  • Sayre, Pennsylvania 18840, United States
  • Upland, Pennsylvania 19013, United States
  • Providence, Rhode Island 02906, United States
  • Charleston, South Carolina 29425, United States
  • Columbia, South Carolina 29209, United States
  • Memphis, Tennessee 38120, United States
  • Houston, Texas 77024, United States
  • Burlington, Vermont 05401, United States
  • Richmond, Virginia 23294, United States
  • Adelaide, 5011, Australia
  • Box Hill, 3128, Australia
  • Brisbane, 4101, Australia
  • Camperdown, 2050, Australia
  • Fitzroy, 3065, Australia
  • Footscray, 3011, Australia
  • Kurralta Park, 5037, Australia
  • Malvern, 3144, Australia
  • Melbourne, 3002, Australia
  • Melbourne, 3181, Australia
  • Perth, 6000, Australia
  • Port Macquarie, 2444, Australia
  • St. Leonards, 2065, Australia
  • Sydney, 2031, Australia
  • Sydney, 2139, Australia
  • Wels, 4600, Austria
  • Wien, 1090, Austria
  • JAÚ, 17210-080, Brazil
  • Rio de Janeiro, 20231-050, Brazil
  • Sao Paulo, 05403-000, Brazil
  • Calgary, Alberta T2N 4N2, Canada
  • Edmonton, Alberta T6G 1Z2, Canada
  • Kelowna, British Columbia V1Y 5L3, Canada
  • North Vancouver, British Columbia V7L 2L7, Canada
  • Surrey, British Columbia V3V 1Z2, Canada
  • Vancouver, British Columbia V5Z 1H5, Canada
  • Victoria, British Columbia V8R 6V5, Canada
  • Winnipeg, Manitoba R2H 2A6, Canada
  • Halifax, Nova Scotia B3H 1V7, Canada
  • Hamilton, Ontario L8V 5C2, Canada
  • London, Ontario N6A 4L6, Canada
  • Mississauga, Ontario L5M 2N1, Canada
  • Oshawa, Ontario L1G 2B9, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • St. Catharines, Ontario L2R 7C6, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M5G 1X5, Canada
  • Toronto, Ontario M5G 2M9, Canada
  • Toronto, Ontario M9N 1N8, Canada
  • Levis, Quebec G6V 3Z1, Canada
  • Montreal, Quebec H1T 2M4, Canada
  • Montreal, Quebec H2L 4M1, Canada
  • Montreal, Quebec H4J 1C5, Canada
  • Quebec City, Quebec G1R 2J6, Canada
  • Beijing, 100021, China
  • Beijing, 100853, China
  • Guangdong, 510515, China
  • Guangzhou, 510060, China
  • Jiangsu, 210009, China
  • Jiangxi, 330000, China
  • Shandong, 250117, China

Showing the first 100 of 236 sites across 33 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Jan 2006 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 10 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2003
First posted
Sep 18, 2003
Start
Jul 2003
Primary completionActual
Jan 2006
CompletionActual
Apr 2009
Results first posted
Jan 22, 2016
Last update
Oct 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00069095
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 18, 2003
Start date
Jul 2003
Primary completion
Jan 2006
Completion
Apr 2009
Results posted
Jan 22, 2016
Last update
Oct 6, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Capecitabine · Bevacizumab

Start the discussion